Study of correlation of ER, PR, HER2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor

Abstract

Background: The receptor status of breast cancer, including ER, PR and HER 2, play a crucial role in the development of treatment plan of breast cancer. Clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well established, added value of PR is less defined. This study aim to know the demography of breast cancer and to document the status of ER, PR and HER 2 status in the north Indian population, as catered by single tertiary care hospital in Lucknow, Uttar Pradesh.Methods: All the patients of breast cancers where surgery or core biopsy was performed for invasive breast carcinoma followed by evaluation of ER, PR and HER 2 status were included in the study from January 2014 to June 2018. Cases were analyzed retrospectively for documentation of ER, PR and HER2 status, using American society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines.Results: 112 patients were included in the study with mean age of 53.70±12.47. Most common histological type was invasive carcinoma of no special type. 43.75% cases were ER+/PR+, 5.35% were ER+/PR-, and 50.89% were ER-/PR-. ER-/PR+ status was seen in none of our cases. Correlation of ER and PR with HER 2 was possible in 90 cases and triple negative breast cancer (TNBC) status was observed in 32.2% of cases.Conclusions: Demography and ER positivity and incidence of TNBC is not different from rest of India, however the clinical utility for evaluation of PR receptor is to be further investigated.

Study of immune histo chemical markers in breast cancer and their correlation with various clinico pathological parameters at tertiary care center in Saurashtra region

“…It was also seen that 23 cases (28.31%) were found to be triple negative breast cancers (TNBC). This was found to be in concordance with the findings of other similar studies [16,22,24] . As we know that Breast carcinoma is a heterogeneous disease with several clinical and histopathological presentations, this is due to several gene expression subtypes and molecular profiles.…”

“…In the present study the mean age of the patients was 51.7 ± 11.01 years with the minimum age of 25 years and the maximum age of 74 years. This is comparable to various similar studies [16,17,18] . Many patients with younger age were also seen in the present study.…”

“…In the present study we found that 45 cases (55.56%) were ER positive and 31 cases (38.27%) were PR positive. This was comparable with study conducted in other parts of the country which showed that the number of cases found to be ER and PR positive are less which makes the response to the hormonal therapy questionable [16,19,20,21] . It was found that there was a decrease in ER positivity with increasing age group which is similar finding in study conducted by Azizun-Nisa et al [22] .…”

“…In the present study we also found that HER2/Neu positivity (+3) was seen in 16 cases (19.75%) which was lower when compared to some studies [22,23,24] while it was higher that the study conducted by Shukla et al [16] . It was also seen that 23 cases (28.31%) were found to be triple negative breast cancers (TNBC).…”

The study of correlation of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer and its incidence in a tertiary center hospital in south India

“…In India, it is also the most common cancer among women and affects them one decade earlier than women in Western countries suggesting that breast cancer occurs at a younger premenopausal age in India. 6 The prognosis of breast cancer depends on several factors including ER/PR/HER2 status. It is now well-established that ER positive tumors are associated with better overall survival compared to ER negative tumors.…”